AC Immune SA announces voluntary suspension of recruitment for its Phase II clinical trial (code-named Retain) for Alzheimer's disease treatment

The company emphasized that this decision is not based on any new security issues or adverse events, but rather stems from internal strategic considerations. This suspension is a temporary measure aimed at optimizing trial processes and resource allocation. AC Immune SA stated that it will decide when to resume patient recruitment based on subsequent evaluation results and is committed to promptly informing investors and regulatory authorities of any progress.